Interní Med. 2002; 4(4): 181-187

Komorové arytmie u chronického srdečního selhání

MUDr. Jana Gandalovičová
II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gandalovičová J. Komorové arytmie u chronického srdečního selhání. Interní Med. 2002;4(4):181-187.

V článku jsou diskutovány možnosti ovlivnění závažných komorových arytmií u pacientů s chronickým srdečním selháním, kteří jsou ohroženi rizikem náhlé srdeční smrti. Je zmíněna etiologie stavů vedoucích k chronickému srdečnímu selhání a patofyziologie komorových arytmií. Jsou diskutovány terapeutické možnosti, hlavně úloha implantabilního kardiovertru - defibrilátoru v primární a sekundární prevenci náhlé smrti u těchto pacientů.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. A comparison of antiarrhytmic drug therapy with implantable cardioverterdefibrillator in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 22: 1576-1583.
    2. Bigger JT, et al. Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery. Circulation 1999; 11: 1416-1421. Go to original source... Go to PubMed...
    3. Buxton AE, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341 (25): 1882-1890. Go to original source... Go to PubMed...
    4. Buxton AE, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 2000; 342 (26): 1937-1945. Go to original source... Go to PubMed...
    5. Cairns JA, et al. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhytmia Trial Investigators. Lancet 1997; 349: 675-682. Go to original source... Go to PubMed...
    6. Connoly SJ, et al. Canadian implantable defibrillators study (CIDS): a randomized trial of the implantable cardioverter-defibrillator against amiodarone. Circulation 2000; 101 (11): 1297-1302. Go to original source... Go to PubMed...
    7. Connoly SJ, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Eue Heart J 2000; 21 (24): 2071-2078. Go to original source... Go to PubMed...
    8. Domanski MJ, et al. Relative effectiveness of the implantable cardioverterdefibrillator and antiarrhytmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhytmias. AVID investigators. Antiarrhytmics versus Implantable Defibrillators. J Am Coll Cardiol 1999; 34 (4): 1090-1095. Go to original source... Go to PubMed...
    9. Doval HC, et al. Randomized trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argetina (GESICA). Lancet 1994; 344 (8921): 493-498. Go to original source... Go to PubMed...
    10. Effect of the antiarrhytmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhytmia Suppression Trial II Incestigators. N Engl J Med 1992; 327 (4): 227-233.
    11. Echt DS, et al. Mortality and morbidity in patients receiving encanaide, flecanaide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324 (12): 781-788. Go to original source... Go to PubMed...
    12. Hohnloser SH, et al. Prevalence, characteristics and prognostic value during long-term follow-up of nonsustained ventricular tachycardia after myocardial infarction in the thrombolytic era. J AM Coll Cardiol 1999; 33 (7): 1895-1902. Go to original source... Go to PubMed...
    13. Julian DG, et al. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349 (9053): 667-674. Go to original source... Go to PubMed...
    14. Klein H, et al. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol 1999; 83 (5B): 91D-97D. Go to original source... Go to PubMed...
    15. Knight BP, et al. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator. J Am Coll Cardiol 1999; 33(7): 1964-1970. Go to original source... Go to PubMed...
    16. Maggioni APOD. Heart Failure: Treatment strategies for heart failure: beta blockers andatiarrhythmics. Heart 2001; 85 (1): 97-103. Go to original source... Go to PubMed...
    17. Maron BJ, et al. Epidemiology of hypertrophic cardiomyopathy: revisited in a large non-referral-based patient population. Circulation 2000; 102 (8): 858-864. Go to original source... Go to PubMed...
    18. Moss AJ, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335 (26): 1933-1940. Go to original source... Go to PubMed...
    19. Myerburg RJ, et al. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993; 119 (12): 1187-1197. Go to original source... Go to PubMed...
    20. Opthof T, et al. Dispersion of refractoriness in normal and ischaemic canine ventricle: effects of sympathetic stimulation. Cardiovasc Res 1993; 27 (11): 1954-1960. Go to original source... Go to PubMed...
    21. Priori SG, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001; 22 (16): 1374-1450. Go to original source... Go to PubMed...
    22. Raitt MH, et al., ,Stable" Ventricular Tachycardia Is Not a Benign Rhythm: Insights From the Antiarrhytmics Versus Implantable Defibrillators (AVID) Registry. Circulation 2001; 103 (2): 244-252. Go to original source... Go to PubMed...
    23. Sanders SE, et al. Survival benefit of the implantable cardioverter-defibrillators in patients on waiting list for cardiac transplantation. Circulation 2001; 104 (12 Suppl 1): I171-176. Go to original source... Go to PubMed...
    24. Sheldon R, et al. Identification of patients most likely to benefit from implantable cardioverter-defibrilllator therapy: the Canadian Implantable Defibrillator Study. Circulation 2000; 101 (14): 1660-1664. Go to original source... Go to PubMed...
    25. Singh SN, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhytmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333 (2): 77-82. Go to original source... Go to PubMed...
    26. Spirito P, et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342 (24): 1778-1785. Go to original source... Go to PubMed...
    27. Tamburro P, et al. Sudden death in idiopathic dilated cardiomyopathy. Am Heart J 1992; 124 (4): 1035-1045. Go to original source... Go to PubMed...
    28. Veenhuyzen GD, et al. Prior coronary artery bypass surgery and risk of death among patients with ischemic left ventricular dysfunction. Circulation 2001; 104 (13): 1489-1493. Go to original source... Go to PubMed...
    29. Waldo AL, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotall. Lancet 1996; 348 (9019): 7-12. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.